Biostax Corp (BTAX)

[locicat1]

The first publication listed in the website that you posted last week was a very recent excellent European clinical study titled "Low Dose Naltrexone for Induction of Remission in Inflammatory Bowel Disease Patients". This study clearly supports the clinical work of Jill Smith, M.D., whose patent, titled " Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists" is licensed to Cytocom, Inc. which is now only less than 10 % owned by IMUN. Everyone should be curious as to what the development status is after the FDA Meeting? Are funds becoming available to initiate the discussed LDN clinical studies with the FDA? What are the approximate time frames? Are the studies to be conducted under the auspices of Cytocom, Inc.?